Ergoteles’s Rallybio RLYB Stock Holding History

Ergoteles’s Portfolio RLYB Stock Details RLYB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,259	Closed	-$57.5K	–	1438
2023 Q1	$57.5K	Buy	+1,259	New	+$65K	﹤0.01%	1131

Other funds holding RLYB

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

PBPIA

Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

CPX

Canaan Partners XI Menlo Park, California $76.1M AUM 638.59% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ergoteles's RLYB Position: Q2 2023 in Review

Ergoteles sold out of Rallybio (RLYB) in Q2 2023, closing a stake of 1,259 shares — an estimated $57.5K sold.

Ergoteles first reported a position in RLYB in Q1 2023 and held it in 1 quarter. The position peaked at $57.5K in Q1 2023. 59 funds tracked by Wall St. Rank hold RLYB as of Q2 2023.

Ergoteles reported no remaining Rallybio position as of Q2 2023 after selling out during the quarter.
Ergoteles sold 1,259 Rallybio shares in Q2 2023, an estimated $57.5K.
Ergoteles first reported a position in Rallybio in Q1 2023 and held it in 1 quarter.
Ergoteles's Rallybio position peaked at $57.5K in Q1 2023.
59 funds tracked by Wall St. Rank held Rallybio as of Q2 2023.

Based on Ergoteles's 13F filing for Q2 2023, filed 14 Aug 2023.